EP Patent

EP3781215A4 — Methods of treating cancer

Assigned to Endocyte Inc · Expires 2021-12-29 · 4y expired

What this patent protects

Patent listed against lutetium-lu-177-vipivotide-tetraxetan.

Drugs covered by this patent

Patent Metadata

Patent number
EP3781215A4
Jurisdiction
EP
Classification
—
Expires
2021-12-29
Drug substance claim
No
Drug product claim
No
Assignee
Endocyte Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.